Consortium
15 beneficiaries and 5 partner organisations
Closing Conference - Molecular and Cellular Pathways of Aging in Hematopoiesis
PROGRAM3rd – 7th May 2023, Heraklion, Greece
Dissemination
our activities and social networks
Closing Conference – Molecular and Cellular Pathways of Aging in Hematopoiesis
We are glad to announce that the ARCH Closing Conference/FEBS Workshop will be held in Heraklion, Greece, from 3rd to 7th May 2023.
Hematopoietic stem cells by ARCH ESRs – European Researchers Night in Madrid
Hematopoiesis in numbers
Beneficiaries
Universita’ Degli Studi Di Milano-Bicocca, Dept. of Biotechnology and Bioscience, Italy
University Medical Center Groningen, ERIBA/ Ageing biology and Stem Cells, Netherland
Centre Europeen De Recherche En Biologie Et Medicine, Dept. Cancer Biology, France.
KING’S COLLEGE LONDON, Molecular Hematology, United Kingdom
Flowmetric Europe S.p.A, Italy
Università Degli Studi Di Roma La Sapienza, Dept. Biology and Biotechnology “C. Darwin”, Italy
University of Veterinary Medicine, Vienna, Institute of Medical Biochemistry, Austria
Max Planck Institute, Dept. of Cellular and Molecular Immunology, Germany
INSERM, Centre de Recherche en Cancérologie de Marseille, France
Agencia Estatal Consejo Superior De Investigaciones Cientificas, Dept. of Cell Proliferation and Development, Spain.
Institut Curie, Genotoxic Stress and Cancer Unit, France
INSTITUT CURIEChristine TRAN QUANG and Jacques GHYSDAELhttps://arch-project.eu/consortium/institut-curie/ – more
TEL AVIV UNIVERSITY (Schneider Children’s Medical Centre), Pediatric Hematological Oncology, Israel
Fondazione M. Tettamanti Menotti De Marchi, M. Tettamanti Research Center, Italy
DIAGENODE, Belgium
Foundation of Biomedical Research, Academy of Athens, Basic Research Center, Greece
Partners
Comitato Maria Letizia Verga
University Autónoma of Madrid
CNR-EMMA-Infrafrontier
Becton Dickinson
Foundation for Research and Technology
Work Package (WP)
WP1: Hematopoiesis stem cells (HSCs) changes during ageing (Months: 8-44) UMCG
Beneficiary: UMCG, CERBM-GIE, FM EU S.P.A. and MPG
WP2: Genetic and epigenetic control of transcription (Months: 8-44) SAPIENZA
Beneficiary: UNIMIB, CERBM-GIE, SAPIENZA, Vetmeduni Vienna and CSIC
WP3:Intrinsic and niche-dependent signalling in acute leukemias (Months: 8-44) INSTITUT CURIE
Beneficiary: INSTITUT CURIE, TAU, FT, DIAGENODE and BRFAA
WP4: Structured training program (Training) (Months: 8-44) UNIMIB
Beneficiary: UNIMIB, UMCG, CERBM-GIE, KCL, FM EU S.P.A., SAPIENZA, Vetmeduni Vienna, MPG, INSERM, CSIC, INSTITUT CURIE, TAU, FT, DIAGENODE and BRFAA
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813091